Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03159390 · ClinicalTrials.gov registry record · NA

Metabolism of Ornithine Phenylacetate

A NA study of Healthy, sponsored by Texas A&M University.

Completed
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT03159390 is a NA study of Healthy that has completed, run by Texas A&M University. The registered enrollment target is 20 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03159390, a NA study of Healthy, has completed, sponsored by Texas A&M University.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

Intravenous infusion of stable tracers of ornithine, glutamine, glutamate, and glycine will be performed, and collect blood samples, urine samples, and muscle biopsies to evaluate the effect of a continuous oral intake of phenylacetate salt of ornithine (OP) on its metabolic fate.

Conditions Studied

Interventions

  • OTHER phenylacetate salt of ornithine

Study Locations (1)

Texas

  • Texas A&M University-CTRAL - College Station

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2015-02-03
Est. Completion 2015-04-30
Phase NA

Sponsor

Texas A&M University

95 total trials

What the Registry Record Tells You About NCT03159390

The ClinicalTrials.gov registry entry for NCT03159390 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The listed sponsor is Texas A&M University, which has 95 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which phenylacetate salt of ornithine is the first listed.

NCT03159390 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03159390 about?

NCT03159390 is a clinical study titled "Metabolism of Ornithine Phenylacetate". Intravenous infusion of stable tracers of ornithine, glutamine, glutamate, and glycine will be performed, and collect blood samples, urine samples, and muscle biopsies to evaluate the effect of a continuous oral intake of phenylacetate salt of ornithine (OP) on its metabolic fate.

What is the current status of trial NCT03159390?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2015-02-03. Estimated completion is 2015-04-30.

What conditions does trial NCT03159390 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT03159390?

The interventions under investigation include: phenylacetate salt of ornithine (OTHER).

Who is sponsoring clinical trial NCT03159390?

This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03159390 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.